TROP2-Targeted, Antibody-Drug

TROP2-Targeted Antibody-Drug Conjugates Set to Transform NSCLC Treatment Market by 2040 | DelveInsight

10.09.2025 - 23:31:31

DelveInsight Business Research, LLP United States of America United Kingdom


+14699457679

Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg

 

Cision View original content:https://www.prnewswire.co.uk/news-releases/trop2-targeted-antibody-drug-conjugates-set-to-transform-nsclc-treatment-market-by-2040--delveinsight-302552562.html

@ prnewswire.co.uk
Lerne live von den Börsen-Profis – melde dich jetzt kostenlos an.